SC 13G: ACHIEVE LIFE SCIENCES, INC.

AI Summary

SC 13G filing by ACHIEVE LIFE SCIENCES, INC..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.0001 — e of Class of Securities: Common Stock, $0.0001 par value per share (e) CUSIP Number
• $0.001 — e of Class of Securities: Common Stock, $0.001 par value per share (e) CUSIP Number

Filing Documents

• propelbiomanagement_sc13g.htm (SC 13G) — 159KB
• 0001829126-24-003471.txt ( ) — 161KB

From the Filing

SC 13G 1 propelbiomanagement_sc13g.htm SC 13G UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___)* Achieve Life Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 004468500 (CUSIP Number) 3/4/2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1. Names of Reporting Persons. Propel Bio Management LLC 2. Check the Appropriate Box if a Member of a Group (a) (b) 3 . SEC Use Only 4 . Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 2,235,247 6. Shared Voting Power 98,929 7. Sole Dispositive Power 2,235,247 8. Shared Dispositive Power 98,929 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,334,176 (1) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares 11. Percent of Class Represented by Amount in Row (9) 6.81% (1)(2) 12. Type of Reporting Person IA (1) The beneficial ownership of the securities reported herein is described in item 4 of this Schedule 13G. (2) Calculations are based on 34,251,911 common shares outstanding as of March 28, 2024, as disclosed by the Issuer on its Form 10-K filed with the Securities and Exchange Commission on March 28, 2024. 1 1. Names of Reporting Persons. Leen Kawas 2. Check the Appropriate Box if a Member of a Group (a) (b) 3. SEC Use Only 4. Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With : 5. Sole Voting Power 2,235,247 6. Shared Voting Power 98,929 7. Sole Dispositive Power 2,235,247 8. Shared Dispositive Power 98,929 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,334,176 (1) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares 11. Percent of Class Represented by Amount in Row (9) 6.81% (1)(2) 12. Type of Reporting Person IN (1) The beneficial (2) Calculations are based on 34,251,911 common shares outstanding as of March 28, 2024, as disclosed by the Issuer on its Form 10-K filed with the Securities and Exchange Commission on March 28, 2024. 2 1. Names of Reporting Persons. Richard Kayne 2. Check the Appropriate Box if a Member of a Group (a) (b) 3. SEC Use Only 4. Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With : 5. Sole Voting Power 2,235,247 6. Shared Voting Power 98,929 7. Sole Dispositive Power 2,235,247 8. Shared Dispositive Power 98,929 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,334,176 (1) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares 11. Percent of Class Represented by Amount in Row (9) 6.81% (1)(2) 12. Type of Reporting Person IN (1) The beneficial (2) Calculations are based on 34,251,911 common shares outstanding as of March 28, 2024, as disclosed by the Issuer on its Form 10-K filed with the Securities and Exchange Commission on March 28, 2024. 3 1. Names of Reporting Persons. Propel Bio Partners LLC 2. Check the Appropriate Box if a Member of a Group (a) (b) 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 2,235,247 6. Shared Voting Power 98,929 7. Sole Dispositive Power 2,235,247 8. Shared Dispositive Power 98,929 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,334,176 (1) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares 11. Percent of Class Represented by Amount in Row (9) 6.81% (1)(2) 12. Type of Reporting Person OO (1) The beneficial (2) Calculations are based on 34,251,911 common shares outstanding as of March 28, 2024, as disclosed by the Issuer on its Form 10-K filed with the Securities and Exchange Commission on March 28, 2024. 4 ITEM 1. (a) Name of Issuer: Achieve Life Sciences, In

View Full Filing

View this SC 13G filing on SEC EDGAR